10-K: Dalrada Financial Corporation Reports Fiscal Year 2024 Results Amidst Restructuring and Strategic Shifts
Sentiment:
Annual Results
Dalrada Financial Corporation's 10-K filing reveals a year of strategic realignment, acquisitions, and financial challenges, including a net loss of $23.25 million.
Capital raiseThe company issued 4,666,665 shares of common stock in a private placement for $604,001.The company converted $13,318,943 of related party debt into preferred stock.The company converted $3,924,499 of related party debt into preferred stock.The company issued 500,000 shares of common stock in connection with a third-party loan.The company issued 109,637 shares of common stock pursuant to the Stock Purchase Agreement with Prakat Solutions Inc.The company issued a total of 500,000 shares of common stock related to earn-out payments in the acquisition of Genefic Specialty Pharmacy.The company issued 500,000 shares of common stock pursuant to a loan agreement.The company issued a total of 1,000,002 shares of common stock related to the acquisition of DepTec (SSCe).The company issued 1,200,000 shares of common stock pursuant to consulting agreements.
Worse than expectedThe company's net loss increased year-over-year, indicating worsening financial performance.The company's revenue decreased year-over-year, indicating a decline in business activity.The company's independent auditors have raised substantial doubt about its ability to continue as a going concern, indicating a significant risk to its future.
Summary
- Dalrada Financial Corporation reported a net loss of $23.25 million for the fiscal year ended June 30, 2024, compared to a net loss of $20.63 million in the previous year.
- The company's total revenue decreased to $25.18 million from $29.74 million in the prior year.
- Genefic, Dalrada's healthcare division, saw a revenue increase of 12.3%, driven by its specialty pharmacy, while its diagnostic labs experienced a significant revenue decrease due to closures.
- Dalrada Precision Manufacturing's revenue decreased by 49.8% due to the loss of a primary customer, while Dalrada Climate Technology's revenue decreased by 48.1% due to the near completion of a major project.
- Dalrada Technologies' revenue decreased by 33% due to the end of several contracts.
- The company's operating expenses decreased by 11.4% to $26.58 million.
- Dalrada's financial statements include a going concern warning from its independent auditors due to significant operating losses and a working capital deficit.
- The company is focusing on growing profitable subsidiaries and reducing investments in less beneficial areas.
- Dalrada acquired Genefic Infusion Rx to expand its pharmacy business.
- The company issued shares of common stock and preferred stock to raise capital and convert debt.
Sentiment
Score: 3
Explanation: The document reveals significant financial challenges, including increased losses, decreased revenue, and a going concern warning. While there are some positive developments, the overall tone is negative due to the company's financial instability and operational issues.
Positives
- Genefic Specialty Pharmacy experienced substantial revenue growth of 453.8% due to new accreditations and contracts.
- Dalrada Career Institute's revenue increased by 22.6% due to new accreditations and increased student enrollment.
- Bothof Brothers Construction revenue increased by 9.1% year-over-year.
- The company reduced its operating expenses by 11.4% year-over-year.
- Dalrada secured an exclusive master distribution agreement with Applied Technologies of NY, Inc. for its heat pumps.
- The company acquired Grand Entrances for $100 in cash, assuming its liabilities and lease.
Negatives
- The company incurred a net loss of $23.25 million for the fiscal year 2024.
- Total revenue decreased by 15.3% year-over-year.
- Dalrada Precision Manufacturing experienced a significant revenue decrease of 49.8% due to the loss of a primary customer.
- Dalrada Climate Technology's revenue decreased by 48.1% due to the near completion of a major project.
- Dalrada Technologies' revenue decreased by 33% due to the end of several contracts.
- The company's independent auditors have raised substantial doubt about its ability to continue as a going concern.
- The company has a working capital deficit of $377,228 as of June 30, 2024.
- Research and development spending was $0 for the year ended June 30, 2024.
Risks
- The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitability.
- The company faces significant competition in its various business segments.
- The company is involved in several legal proceedings, which could result in significant financial liabilities.
- The company's reliance on related party debt and equity financing poses a risk to its financial stability.
- The company's internal controls over financial reporting have been identified as having material weaknesses.
- The company's revenue is highly dependent on a few key customers and contracts.
Future Outlook
The company anticipates an increase in sales of Likido's heat pumps and expects positive results from the U.S. Government's testing program, which should accelerate market adoption. The company also plans to continue to pursue synergistic opportunities to enhance its business portfolio.
Management Comments
- The Company continues to rely on equity and debt investors to finance its losses, it is implementing plans to achieve cost savings and other strategic objectives to address Company profitability.
- In addition to raising debt and equity financing, the Company continues to focus on growing the subsidiaries anticipated to be most profitable while reducing investments in areas that are not expected to have long-term benefits.
- The Company will continue to pursue synergistic opportunities to enhance its business portfolio.
Industry Context
The company's focus on climate technology aligns with the growing global emphasis on sustainability and clean energy solutions. The healthcare division's expansion into specialty pharmacy addresses a growing market need. However, the company faces competition from established players in these sectors.
Comparison to Industry Standards
- Dalrada's revenue decline contrasts with the growth seen in some segments of the renewable energy and healthcare industries.
- The company's net loss is significantly higher than many of its peers in the technology and manufacturing sectors.
- The company's reliance on related party financing is not typical for publicly traded companies and raises concerns about financial independence.
- The company's lack of R&D spending is unusual for a company that claims to be focused on innovation.
- The company's internal control weaknesses are a significant concern and are not typical for a publicly traded company.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Heather McMahon | October 15, 2024 | Resignation | |
| Director | Vince Monteparte | October 11, 2024 | Resignation | |
| Director | Roger Campos | October 23, 2024 | Nomination |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Auditor Change | Assurance Dimensions resigned as the company's auditor and CM3 Advisory was engaged as the new auditor. | October 12, 2024 and October 18, 2024 | This change may impact investor confidence and requires careful monitoring of the new auditor's performance. |
Legal Proceedings
- Genefic Products is in litigation with Vivera Pharmaceuticals, Inc. for misappropriation of funds.
- Kroger Specialty Pharmacy LLC filed lawsuits against Genefic Specialty Pharmacy and two of its employees.
- Asset Group, Inc. filed a breach of contract with Dalrada Health Products.
- MDIQ filed a breach of contract with Dalrada Financial Corporation.
- Dalrada Financial Corporation filed a lawsuit against DePrey Company and Simon Gray for breach of contract and intentional interference with contractual relationships.
- Dalrada Financial Corporation filed a case against Stuart Cox for fraud, breach of contract, and unjust enrichment.
Related Party Transactions
- The company received cash funding or expenses paid on its behalf from related parties totaling $2,923,418 during the year ended June 30, 2024.
- The company incurred expenses for services provided by related parties totaling $5,312,020 during the year ended June 30, 2023.
- The company's Bothof Brothers subsidiary recognized revenue for construction services totaling $2,134,470 from related parties during the year ended June 30, 2023.
- The company's DES subsidiary recognized monthly interest income and royalty revenue totaling $45,968 from related parties during the year ended June 30, 2023.
- The company incurred $1,669,788 in services performed by non-employee board members during the year ended June 30, 2023.
- Several related party debt convertible notes occurred during 2024 and 2023.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and going concern warning.
- Employees may be affected by potential cost-cutting measures and restructuring.
- Customers may experience disruptions due to the company's financial challenges.
- Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.
Next Steps
- The company plans to continue to pursue synergistic opportunities to enhance its business portfolio.
- The company expects to fund any short-term operational deficits primarily through collection of outstanding accounts receivable, pharmaceutical sales, the sale of DCT commercial and residential heat pumps as well as loans from related parties.
- The company is implementing plans to achieve cost savings and other strategic objectives to address Company profitability.
Key Dates
| Date | Description |
|---|---|
| September 1982 | Dalrada was incorporated in California. |
| May 1983 | Dalrada was reincorporated in Delaware. |
| May 5, 2020 | Dalrada was reincorporated in Wyoming. |
| July 9, 2020 | The Board authorized the Dalrada Financial Corporation 2020 Stock Compensation Plan. |
| May 10, 2020 | The company received an Economic Injury Disaster Loan (EIDL). |
| August 2021 | Dalrada entered a joint venture with Vivera Pharmaceuticals, Inc. for Pala Diagnostics. |
| February 25, 2021 | The Company amended the 2020 Stock Compensation Plan. |
| November 10, 2021 | The Company cancelled 6,500,000 shares and issued 6,500,000 cashless warrants. |
| December 2021 | Dalrada Health filed suit against Vivera and Paul Edalat. |
| February 1, 2022 | $6,532,206 of related party debt was converted into Series G Convertible Preferred Stock. |
| February 16, 2022 | The Company issued 2,250,000 cashless warrants to new board members. |
| April 6, 2022 | The Company entered into an acquisition agreement with Silicon Services Consortium Ltd. (SSCe). |
| October 17, 2022 | The Company acquired Bothof Brothers Construction Inc. |
| March 1, 2023 | The Company acquired Dalrada Technology LTD EU (DTL). |
| April 4, 2023 | $4,544,224 of related party debt was converted into Series H Convertible Preferred Stock. |
| June 23, 2023 | $29,315,320 of related party debt was converted into Series I Convertible Preferred Stock. |
| July 2023 | The Company issued 500,000 shares of common stock in connection with a third-party loan. |
| July 2023 | The Company issued 109,637 shares of common stock pursuant to the Stock Purchase Agreement with Prakat Solutions Inc. |
| September 2023 | Kroger Specialty Pharmacy LLC filed lawsuits against Genefic Specialty Pharmacy. |
| September 2023 | Asset Group, Inc. filed a breach of contract with Dalrada Health Products. |
| September and December 2023, April and May 2024 | The Company issued a total of 500,000 shares of common stock related to earn-out payments in the acquisition of Genefic Specialty Pharmacy. |
| October 2023 | The company issued 500,000 shares of common stock pursuant to a loan agreement. |
| December 2023 and April 2024 | The Company issued a total of 1,000,002 shares of common stock related to the acquisition of DepTec (SSCe). |
| January 4, 2024 | The Company executed a revenue purchase agreement with NewCo Capital Group LLC. |
| February 2024 | The Company issued 4,666,665 shares of common stock related to a private placement. |
| February 2024 | The Company issued 1,200,000 shares of common stock pursuant to consulting agreements. |
| February 2024 | Dalrada Home Corporation was established. |
| March 2024 | MDIQ filed a breach of contract with Dalrada Financial Corporation. |
| March 29, 2024 | $13,318,783 of related party debt was converted into Series I Convertible Preferred Stock. |
| April 2024 | The Court in the Tennessee case granted the preliminary injunction on the Tennessee employee. |
| April 8, 2024 | The Company entered into a promissory note with 1800 Diagonal Lending, LLC. |
| May 2, 2024 | The Company executed a revenue purchase agreement with Credit Line Capital Group. |
| May 13, 2024 | The Company acquired 100% of IV Services, LLC dba Genefic Infusion Rx. |
| May 16, 2024 | The Company entered into a promissory note with 1800 Diagonal Lending, LLC. |
| May 16, 2024 | The Company entered into a term loan with Agile Capital Funding, LLC. |
| May 22, 2024 | Valuation Shortfall shares were issued into Series I Convertible Preferred Stock. |
| June 2024 | Dalrada Financial Corporation filed a case against Stuart Cox. |
| June 25, 2024 | The Company executed a revenue purchase agreement with Cucumber Capital LLC. |
| June 30, 2024 | $3,924,499 of related party debt was converted into Series I Convertible Preferred Stock. |
| July 10, 2024 | The Company entered into a promissory note with 1800 Diagonal Lending, LLC. |
| July 18, 2024 | The Company executed a cash advance agreement with Cali Flower Capital Inc. |
| July 25, 2024 | The Company executed a revenue purchase agreement with 24 Capital. |
| July 29, 2024 | The Company executed a revenue purchase agreement with Tycoon Capital Group. |
| August 12, 2024 | The Company entered into an Exclusive Master Distribution Agreement with Applied Technologies of NY, Inc. |
| August 15, 2024 | The Company signed a lease for manufacturing and office space in Portland, Oregon. |
| August 19, 2024 | The Company acquired Grand Entrances. |
| August 23, 2024 | The Company executed a revenue purchase agreement with Quick Funding. |
| September 20, 2024 | The Company executed a revenue purchase agreement with QFS Capital, LLC. |
| October 11, 2024 | Vince Monteparte resigned as a member of the Companys Board of Directors. |
| October 12, 2024 | Assurance Dimensions resigned as the Companys auditor. |
| October 15, 2024 | Heather McMahon resigned as member of the Companys Board of Directors. |
| October 18, 2024 | The Company engaged CM3 Advisory as its new auditor. |
| October 23, 2024 | The Company nominated Roger Campos as a member of the Companys Board of Directors. |
Keywords
Dalrada Financial Corporation, financial results, healthcare, climate technology, manufacturing, technology, pharmacy, heat pumps, acquisitions, legal proceedings, financial statements, revenue, net loss, operating expenses, internal controls, going concern
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.